Heart-gut axis: Targeting proprotein convertase subtilisin/kexin type 9 (PCSK9) to prevent cardiovascular disease through gut microbiota
Author:
- Charan Reddy KvCKCharan Reddy Kv
Open Access
- 1 March 2021
- journal article
- Published by Elsevier in Medicine in Microecology
- Vol. 7
Abstract
No abstract availableKeywords
This publication has 86 references indexed in Scilit:
- Plasma PCSK9 concentrations during an oral fat load and after short term high-fat, high-fat high-protein and high-fructose dietsNutrition & Metabolism, 2013
- Symptomatic atherosclerosis is associated with an altered gut metagenomeNature Communications, 2012
- Analysis of gut microbial regulation of host gene expression along the length of the gut and regulation of gut microbial ecology through MyD88Gut, 2011
- Human oral, gut, and plaque microbiota in patients with atherosclerosisProceedings of the National Academy of Sciences, 2010
- LPS-induced autophagy is mediated by oxidative signaling in cardiomyocytes and is associated with cytoprotectionAmerican Journal of Physiology-Heart and Circulatory Physiology, 2009
- Microbes in Gastrointestinal Health and DiseaseGastroenterology, 2009
- The Human Microbiome ProjectNature, 2007
- Sequence Variations inPCSK9,Low LDL, and Protection against Coronary Heart DiseaseNew England Journal of Medicine, 2006
- Apolipoprotein B100 Metabolism in Autosomal-Dominant Hypercholesterolemia Related to Mutations inPCSK9Arteriosclerosis, Thrombosis, and Vascular Biology, 2004
- Mutations in PCSK9 cause autosomal dominant hypercholesterolemiaNature Genetics, 2003